Company intelligence / Profile preview

Fuzionaire

The Woodlands, Texas, United States

Ownership: Private
Development stage: Other

Overview

Fuzionaire has developed a proprietary radiopharmaceutical platform based on breakthrough chemistry from Nobel laureate Robert Grubbs' lab at Caltech. The company's HetSiFA® library enables rapid production of fluorine-18 radiopharmaceuticals for PET imaging and development of theranostic pairs combining PET diagnostics with radioligand therapies. The platform can create chemically identical diagnostic and therapeutic companions, enabling personalized cancer care. Early development focuses on GRPR-targeting theranostic pairs for prostate and breast cancer

Therapeutic areas: OncologyNeurology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

McGill UniversityThe Neuro (Montreal Neurological Institute-Hospital)McMaster UniversityETH ZurichNihon Medi-Physics Co., Ltd.Japan Medical Isotope Technology Development K.K.

Beyond the preview

Go deeper on Fuzionaire.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzionaire.

Explore the full profile